EU/3/11/850: Orphan designation for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)

Darinaparsin

Overview

On 15 April 2011, orphan designation (EU/3/11/850) was granted by the European Commission to Ziopharm Oncology Limited, United Kingdom, for darinaparsin for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated).

Key facts

Active substance
Darinaparsin
Intended use
Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
Orphan designation status
Positive
EU designation number
EU/3/11/850
Date of designation
15/04/2011
Sponsor

IDEA Innovative Drug European Associates (Ireland) Limited

Unit 13 Classon House
Dundrum Business Park
Dundrum Road
Dublin 14
D14 W9Y3
Ireland

E-mail: inquires@krystalbio.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

Date Update
July 2022 The sponsor’s address was updated in July 2022.
February 2019 The sponsorship was transferred to IDEA Innovative Drug European Associates (Ireland) Limited, Republic of Ireland, in February 2019.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating